United Therapeutics (UTHR) CEO Rothblatt Buys $1.3M of Stock
CEO Martine Rothblatt buys 9,500 shares of United Therapeutics, valued at $1.29 million, showing confidence in the company's future.
Reviewed by automated data checks against the source filing. How we make and check alerts
Martine Rothblatt, Chairperson & CEO at United Therapeutics Corporation ($UTHR), bought 9,500 shares at an average price of $135.42, worth about $1.29 million, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $UTHR is up 0.8% after 1 week, down 2.7% after 1 month and down 1.8% to date (from the $542.66 close on Jun 26, 2026).
UTHR
United Therapeutics Corporation
Key Points
- Martine Rothblatt bought 9,500 shares of United Therapeutics for about $1.29 million at a price of $135.42 per share on June 25, 2026.
- The stock closed at $538.40 on the day of the transaction, significantly higher than its 52-week low of $409.07.
- United Therapeutics, a company focused on developing treatments for chronic diseases, has a market cap of about $21.1 billion.
Get $UTHR trade alerts by text
We text you when insiders, Congress or big funds trade $UTHR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated United Therapeutics Corporation alert may contain errors. Disclosures
Martine Rothblatt's Recent Purchase
Martine Rothblatt, the Chairperson and CEO of United Therapeutics Corporation (NasdaqGS: UTHR), bought 9,500 shares on June 25, 2026, for approximately $1.29 million. The shares were purchased at a price of $135.42 each, reflecting her continued investment in the company.
Insider Buying and Selling at United Therapeutics Corporation
This latest purchase marks a significant commitment from Rothblatt, who has been active in the market recently. She has made several transactions in June 2026, including selling 9,500 shares on June 26 and buying the same amount just a day earlier. This pattern suggests a dynamic approach to her holdings in United Therapeutics.
How United Therapeutics Corporation Stock Has Traded
On June 25, 2026, the stock was trading at $538.40, well above its 52-week low of $409.07. The stock has seen fluctuations lately, with a high of $609.35 in the past year. This purchase comes at a time when the stock has been performing strongly, indicating Rothblatt's confidence in its future prospects.
Recent Earnings
In its latest earnings report, United Therapeutics reported revenue of approximately $3.15 billion, with a net margin of about 41.6%. The company has faced some revenue growth challenges recently, showing a slight decline of 1.9%. The next earnings report is scheduled for October 28, 2026.
Insider Buying and Selling at United Therapeutics Corporation
In addition to Rothblatt's recent purchase, CFO James Edgemond bought 10,000 shares on June 18, 2026, at a price of $146.03 each, totaling about $1.46 million. This shows that top executives are actively investing in the company, which may signal confidence in its future performance.
Analysts Set New Price Targets
Analysts have a generally positive outlook on United Therapeutics. On October 1, 2026, BTIG upgraded the stock to a Buy rating with a price target of $728. RBC Capital maintained an Outperform rating with a target of $708 on October 8, 2026. With a consensus rating of Buy and an average target price of $664.33, analysts remain optimistic about the company's growth potential.
About United Therapeutics
United Therapeutics Corporation focuses on developing and commercializing treatments for chronic and life-threatening diseases. The company’s innovative products aim to meet the medical needs of patients, making it a key player in the healthcare sector.
What's Ahead for United Therapeutics Corporation
Investors will be watching for United Therapeutics' next earnings report on October 28, 2026, for updates on financial performance and future guidance. Meanwhile, Rothblatt's recent buying activity highlights her ongoing commitment to the company's success amidst a fluctuating market.
Related Filing Alerts
Source: Martine Rothblatt's Form 4 filing on $UTHR (Jun 26, 2026). Find the original filing: UTHR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts